Biological and Clinical Aspects of Metastatic Spinal Tumors

Litak, Jakub; Czyżewski, Wojciech; Szymoniuk, Michał; Sakwa, Leon; Pasierb, Barbara; Litak, Joanna; Hoffman, Zofia; Kamieniak, Piotr; Roliński, Jacek

doi:10.3390/cancers14194599

Cited by 17 publications

(7 citation statements)

References 295 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their ability to differentiate in multiple directions and to secrete a variety of bioactive factors make them promising for a wide range of applications in autologous stem cell transplantation. In addition, the potential of ADMSCs in neural differentiation has been recognized ( Litak et al, 2022 ), and these ADMSCs-derived neural cells have been shown to promote neural repair. More importantly, ADMSCs exhibit low immunogenicity and tumorigenicity.…”

Section: Combined Application Of Biomaterialsmentioning

confidence: 99%

Biomaterials targeting the microenvironment for spinal cord injury repair: progression and perspectives

Gao,

Wang,

et al. 2024

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Spinal cord injury (SCI) disrupts nerve pathways and affects sensory, motor, and autonomic function. There is currently no effective treatment for SCI. SCI occurs within three temporal periods: acute, subacute, and chronic. In each period there are different alterations in the cells, inflammatory factors, and signaling pathways within the spinal cord. Many biomaterials have been investigated in the treatment of SCI, including hydrogels and fiber scaffolds, and some progress has been made in the treatment of SCI using multiple materials. However, there are limitations when using individual biomaterials in SCI treatment, and these limitations can be significantly improved by combining treatments with stem cells. In order to better understand SCI and to investigate new strategies for its treatment, several combination therapies that include materials combined with cells, drugs, cytokines, etc. are summarized in the current review.

show abstract

Section: Combined Application Of Biomaterialsmentioning

confidence: 99%

Biomaterials targeting the microenvironment for spinal cord injury repair: progression and perspectives

Gao,

Wang,

et al. 2024

Front. Cell. Neurosci.

View full text Add to dashboard Cite

show abstract

“…In the course of spine disorders, pain symptoms commonly occur [ 11 , 12 ]. According to available epidemiological studies, a neuropathic component of pain is often present in patients with spinal diseases, with a frequency ranging from 36% to 55% of patients [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Diagnosis and Management of Neuropathic Pain in Spine Diseases

Bielewicz

Kamieniak

Szymoniuk

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

Neuropathic pain is generally defined as a non-physiological pain experience caused by damage to the nervous system. It can occur spontaneously, as a reaction to a given stimulus, or independently of its action, leading to unusual pain sensations usually referred to as firing, burning or throbbing. In the course of spine disorders, pain symptoms commonly occur. According to available epidemiological studies, a neuropathic component of pain is often present in patients with spinal diseases, with a frequency ranging from 36% to 55% of patients. Distinguishing between chronic nociceptive pain and neuropathic pain very often remains a challenge. Consequently, neuropathic pain is often underdiagnosed in patients with spinal diseases. In reference to current guidelines for the treatment of neuropathic pain, gabapentin, serotonin and norepinephrine reuptake inhibitors and tricyclic antidepressants constitute first-line therapeutic agents. However, long-term pharmacologic treatment often leads to developing tolerance and resistance to used medications. Therefore, in recent years, a plethora of therapeutic methods for neuropathic pain have been developed and investigated to improve clinical outcomes. In this review, we briefly summarized current knowledge about the pathophysiology and diagnosis of neuropathic pain. Moreover, we described the most effective treatment approaches for neuropathic pain and discussed their relevance in the treatment of spinal pain.

show abstract

“…The treatment of spine metastases is mostly palliative, and it is aimed at preserving or improving quality of life, as well as the protection or restoration of neurological functions and spinal stability [ 3 ]. Currently, bone-targeted agents are the mainstay of treatment of spine metastases, and their use can limit the incidence of SREs; however, their influence on survival is rather limited [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

The Role of Cytokines in the Metastasis of Solid Tumors to the Spine: Systematic Review

Łabędź

Przybyla

Zimna

et al. 2023

IJMS

View full text Add to dashboard Cite

Although many studies have investigated the role of cytokines in bone metastases, our knowledge of their function in spine metastasis is limited. Therefore, we performed a systematic review to map the available evidence on the involvement of cytokines in spine metastasis in solid tumors. A PubMed search identified 211 articles demonstrating a functional link between cytokines/cytokine receptors and bone metastases, including six articles confirming the role of cytokines/cytokine receptors in spine metastases. A total of 68 cytokines/cytokine receptors were identified to mediate bone metastases; 9 (mostly chemokines) played a role in spine metastases: CXC motif chemokine ligand (CXCL) 5, CXCL12, CXC motif chemokine receptor (CXCR) 4, CXCR6, interleukin (IL) 10 in prostate cancer, CX3C motif chemokine ligand (CX3CL) 1 and CX3C motif chemokine receptor (CX3CR) 1 in liver cancer, CC motif chemokine ligand (CCL) 2 in breast cancer, and transforming growth factor (TGF) β in skin cancer. Except for CXCR6, all cytokines/cytokine receptors were shown to operate in the spine, with CX3CL1, CX3CR1, IL10, CCL2, CXCL12, and CXCR4 mediating bone marrow colonization, CXCL5 and TGFβ promoting tumor cell proliferation, and TGFβ additionally driving bone remodeling. The number of cytokines/cytokine receptors confirmed to mediate spinal metastasis is low compared with the vast spectrum of cytokines/cytokine receptors participating in other parts of the skeleton. Therefore, further research is needed, including validation of the role of cytokines mediating metastases to other bones, to precisely address the unmet clinical need associated with spine metastases.

show abstract

Biological and Clinical Aspects of Metastatic Spinal Tumors

Cited by 17 publications

References 295 publications

Biomaterials targeting the microenvironment for spinal cord injury repair: progression and perspectives

Biomaterials targeting the microenvironment for spinal cord injury repair: progression and perspectives

Diagnosis and Management of Neuropathic Pain in Spine Diseases

The Role of Cytokines in the Metastasis of Solid Tumors to the Spine: Systematic Review

Contact Info

Product

Resources

About